Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage oncology company developing treatments for cancers with critical unmet medical need.

End of road sign on street

Biotech

Oncternal sells cancer assets to mystery biotech, winds down ops

Oncternal’s ROR1 programs have gone out with a whimper, offloaded to Ho’ola Therapeutics for $3 million upfront as the biotech winds down operations.

Nick Paul Taylor Jul 1, 2025 9:38am

playing cards

Oncternal stock sinks 60% amid layoffs, trial terminations

Sep 12, 2024 10:51am

Red blood cells

Oncternal reports patient death in CAR-T dose-escalation study

Dec 28, 2023 10:52am

dominoes fall stop fail investigation

Facing a crowded market for BTK inhibitors, Oncternal bows out

Apr 4, 2023 4:00am